CoVPN 3502/REGN 2069: Regeneron’s REGEN-COV Antibody Cocktail

Read the latest news releases:  

CoVPN 3502/REGN 2069 tested the combination of two antibodies’ (casirivimab and imdevimab antibody cocktail) ability to prevent acquisition of SARS-CoV-2. This study enrolled approximately 3,300 adults and adolescents in North America and Europe who shared a household with a person who recently tested positive for SARS-CoV-2.  

Volunteers could be SARS-CoV-2 negative at enrollment or have acquired SARS-CoV-2 but did not have any COVID-19 symptoms. The REGEN-COV antibody cocktail was designed to bind to SARS-CoV-2 and prevent the virus from entering healthy cells. The REGEN-COV antibodies were made in a lab by the pharmaceutical company Regeneron. The REGEN-COV antibody cocktail cannot give you SARS-CoV-2, nor will it make you sick with COVID-19.

Learn more about the Regeneron monoclonal antibody clinical study and the antibodies used: 

Together we can help end uncertainty. Join us.

We need your help to keep learning and improving vaccines against COVID-19. We made history with safe and effective vaccines and we’ll keep working as long as there are people to protect, variants emerging, and research answers needed to end this pandemic. To participate:

  • Fill out the survey again so we have your most current information to match you with a study, even if you filled it out previously!
  • If you haven’t registered to volunteer before, sign up today. There’s still a lot we can do together for those we love.


Content last reviewed on June 12, 2021